SNYSanofiSigning up patients
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 104 (planned)
- Started
- Oct 9, 2025
- Main results expected
- Oct 13, 2027
- Fully finished
- Jul 22, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of ocular and non-ocular treatment-emergent adverse events (TEAEs)
Measured over: Day 1 to Week 104
Incidence and severity of ocular and non-ocular treatment-emergent serious adverse events (TESAEs)
Measured over: Day 1 to Week 104
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07215234 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC